Tag: lixte biotechnology

December 4, 2019

Lixte Biotechnology Enrolls First Patients in LB-100 Study

The first two patients out of eight have been enrolled testing its lead product, LB-100, in brain tumor patients.
August 21, 2018

Lixte Biotechnology Announces Clinical Trial Agreement

The clinical trial and exclusive license agreement will allow Lixte to conduct a Phase 1b study of the safety and...
August 21, 2018

Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome

Lixte Biotechnology (OTCQB:LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement with Moffitt Cancer Center to conduct...